Top Insider-Owned Growth Companies For October 2024

As global markets navigate a mix of economic signals, with the S&P 500 advancing and European indices buoyed by rate cuts, investors are keenly observing sectors like technology that have shown resilience amid fluctuating conditions. In this environment, growth companies with high insider ownership can be particularly appealing as they often signal confidence from those who know the business best, aligning their interests closely with shareholders.

Top 10 Growth Companies With High Insider Ownership

Name	Insider Ownership	Earnings Growth
Lavvi Empreendimentos Imobiliários (BOVESPA:LAVV3)	11.9%	21.1%
Atlas Energy Solutions (NYSE:AESI)	29.1%	41.9%
Clinuvel Pharmaceuticals (ASX:CUV)	10.4%	27.4%
KebNi (OM:KEBNI B)	36.3%	86.1%
Findi (ASX:FND)	35.8%	64.8%
HANA Micron (KOSDAQ:A067310)	18.3%	105.8%
Credo Technology Group Holding (NasdaqGS:CRDO)	13.9%	95%
Adveritas (ASX:AV1)	21.2%	144.2%
Plenti Group (ASX:PLT)	12.8%	106.4%
UTI (KOSDAQ:A179900)	33.1%	134.6%

Click here to see the full list of 1486 stocks from our Fast Growing Companies With High Insider Ownership screener.

Let's uncover some gems from our specialized screener.

Kaili Catalyst & New MaterialsLtd (SHSE:688269)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Kaili Catalyst & New Materials Co., Ltd. is involved in the research, development, production, and sale of metal catalysts both in China and internationally, with a market cap of CN¥3.65 billion.

Operations: Revenue segments for SHSE:688269 include the research, development, production, and sale of metal catalysts in both domestic and international markets.

Insider Ownership: 10.9%

Earnings Growth Forecast: 63.6% p.a.

Kaili Catalyst & New Materials Ltd. faces challenges with declining profit margins and reduced half-yearly earnings, yet it remains a growth prospect due to significant forecasted earnings growth of 63.6% annually over the next three years, outpacing the Chinese market average. Despite no recent insider trading activity, its revenue is expected to grow at 29.6% per year, surpassing market expectations. However, dividend sustainability is questionable given current coverage by earnings and cash flows.

• Dive into the specifics of Kaili Catalyst & New MaterialsLtd here with our thorough growth forecast report.
• Our expertly prepared valuation report Kaili Catalyst & New MaterialsLtd implies its share price may be too high.

Zbit Semiconductor (SHSE:688416)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Zbit Semiconductor, Inc. is an integrated circuit design company in China specializing in the research, development, design, and sale of memory and MCU chips with a market cap of CN¥2.79 billion.

Operations: The company's revenue primarily comes from its semiconductors segment, which generated CN¥331.75 million.

Insider Ownership: 28.8%

Earnings Growth Forecast: 178.5% p.a.

Zbit Semiconductor is poised for substantial growth, with revenue projected to increase by 37.7% annually, outpacing the Chinese market's 13.5% rate. Despite a volatile share price and no recent insider trading activity, the company is expected to become profitable within three years, surpassing average market growth rates. Recent earnings reports show increased sales of CNY 177.36 million but a widened net loss of CNY 74.35 million compared to last year.

• Click to explore a detailed breakdown of our findings in Zbit Semiconductor's earnings growth report.
• Upon reviewing our latest valuation report, Zbit Semiconductor's share price might be too optimistic.

Jiangsu Jibeier Pharmaceutical (SHSE:688566)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Jiangsu Jibeier Pharmaceutical Co., Ltd. is a pharmaceutical company involved in the research, development, production, and sale of chemical pharmaceutical preparations, Chinese medicine, and drugs with a market cap of CN¥4.95 billion.

Operations: The company's revenue primarily comes from its pharmaceutical manufacturing segment, amounting to CN¥875.78 million.

Insider Ownership: 33.3%

Earnings Growth Forecast: 21.3% p.a.

Jiangsu Jibeier Pharmaceutical is set for significant growth, with revenue expected to rise by 22% annually, outpacing the Chinese market. Despite past shareholder dilution and a low forecasted return on equity of 14.2%, its price-to-earnings ratio of 20.2x suggests good value relative to peers. Recent earnings show improved performance, with net income reaching CNY 122.01 million for the half-year ending June 2024, up from CNY 96.26 million last year.

• Take a closer look at Jiangsu Jibeier Pharmaceutical's potential here in our earnings growth report.
• The valuation report we've compiled suggests that Jiangsu Jibeier Pharmaceutical's current price could be quite moderate.

Summing It All Up

• Click through to start exploring the rest of the 1483 Fast Growing Companies With High Insider Ownership now.
• Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.
• Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors.

Contemplating Other Strategies?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com